AZ’s antibody first to be cleared by FDA for COVID prevention
AstraZeneca’s antibody cocktail for COVID-19, now called Evushield, has become the first drug in the class to be authorised for prevention of infection by the […]
AstraZeneca’s antibody cocktail for COVID-19, now called Evushield, has become the first drug in the class to be authorised for prevention of infection by the […]
Shots: The P-III PROVENT & TACKLE trial evaluates AZD7442 (IM) vs PBO in a ratio (2:1) & (1:1) in 5197 & 903 patients with COVID-19 […]
As expected, Merck & Co has moved ahead swiftly with an emergency use application for its oral antiviral molnupiravir, aiming to protect people with mild […]
Shots: The P-III TACKLE trial evaluates the safety & efficacy of AZD7442 (600mg, IM) as monothx. vs PBO in a ratio (1:1) in 903 outpatients […]
AstraZeneca has sought emergency use authorisation for its antibody combination AZD7442, following trial results indicating it can prevent symptomatic COVID-19 infection when given to healthy […]
AstraZeneca’s AZD7442 has shown that it can prevent COVID-19 infection when given to healthy patients – the first time this has been demonstrated by a […]
The drug, AZD7442, is designed to potentially provide at least six months of protection from Covid-19. The trial, which is funded by federal defense and […]
The first patients have been dosed in a trial of two AstraZeneca antibodies, collectively known as AZD7442, that are being developed to both treat and […]
Shots: The first participants have been dosed in a P-I trial of AZD7442 to assess safety, tolerability, and PK of the combination mAbs in up […]
Copyright © 2024 | WordPress Theme by MH Themes